Seastar Medical Holding CORP 8-K Filing

FAQ

Key Financial Figures

• $0.0001 — ich registered Common Stock par value $0.0001 per share ICU The Nasdaq Stock Mark
• $11.50 — sable for one share of Common Stock for $11.50 per share ICUCW The Nasdaq Stock Ma
• $15,000 — Messinger will receive a monthly fee of $15,000, and the Company can terminate the Cons

Filing Documents

• icu20251111c_8k.htm (8-K) — 34KB
• ex_886639.htm (EX-10.1) — 49KB
• ex_886488.htm (EX-99.1) — 13KB
• seastarlogo2.jpg (GRAPHIC) — 6KB
• 0001437749-25-035449.txt ( ) — 274KB
• icu-20251112.xsd (EX-101.SCH) — 4KB
• icu-20251112_def.xml (EX-101.DEF) — 14KB
• icu-20251112_lab.xml (EX-101.LAB) — 19KB
• icu-20251112_pre.xml (EX-101.PRE) — 14KB
• icu20251111c_8k_htm.xml (XML) — 5KB

02

Item 5.02 Departure of Directors or Certain Officer; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 12, 2025, the Board of Directors (the "Board") of SeaStar Medical Holding Corporation (the "Company") appointed Michael Messinger age 51, as the Company's Chief Financial Officer, effective November 14, 2025. Mr. Messinger has more than two decades of experience and leadership in financing and accounting for drug discovery and development organizations. He has served as a member of the board of directors of Filament Health Corp. since March 2024 and a strategic consultant to various biotechnology companies since January of 2024. Mr. Messinger most recently served as Chief Financial Officer of ContraFect Corporation, a biotechnology company focused on treatments for life-threatening bacterial infections in the hospital setting, from October 2018 to November 2023, where he led the company through multiple financing rounds, including investments from Pfizer Inc., and a contract with BARDA (Biomedical Advanced Research and Development Authority). Prior to becoming the Chief Financial Officer of ContraFect, Mr. Messinger held senior financial roles at ContraFect, Lexicon Pharmaceuticals, Inc. and Coelacanth Corporation. He started his career as an auditor at Ernst & Young LLP. Mr. Messinger received his B.B.A. degree in accounting from the University of Michigan. Pursuant to the terms of the consulting agreement between Mr. Messinger and the Company, dated October 31, 2025 (the "Consulting Agreement"), Mr. Messinger will receive a monthly fee of $15,000, and the Company can terminate the Consulting Agreement at any time with 30 days' notice. The foregoing summary of the Consulting Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Consulting Agreement, which is attached as Exhibit 10.1 to this Current Report on Form 8-K and is incorporate

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1# Consulting Agreement dated October 31, 2025, by and between the Company and Michael Messinger 99.1 Press Release dated November 17, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) Indicates management contract or compensatory plan or arrangement # Certain of the exhibits and schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5). The Registrant agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request; provided, however, that the Registrant may request confidential treatment pursuant to Rule 24b-2 of the Exchange Act, as amended, for any schedule or exhibit so furnished.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SeaStar Medical Holding Corporation By: /s/ Eric Schlorff Date: November 17, 2025 Name: Eric Schlorff Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR